
    
      This is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and
      safety of IV ganaxolone in status epilepticus. Investigational product will be added to
      standard of care before IV anesthetic during the treatment of SE. Subjects will be screened
      for inclusion/exclusion criteria prior to receiving investigational product by continuous IV
      infusion. Subjects will be followed for approximately 4 weeks.

      Subjects who are known to be at risk for SE may be consented or assented prior to an SE
      event.
    
  